Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]
Discontinued
Reference number: GID-TA10413
The company have announced that they will no longer be pursuing a Marketing Authorisation Application to the European Medicines Agency for Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer following the results of the KEYNOTE-604 trial data.
Therefore NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.